CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$2.83
0.00 (0.00%)
▲
5d:
-1.05%
30d:
-1.05%
90d:
+7.2%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Smart Money Accumulation
None View Scanner →
Strength: 5.8/10
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 2.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 2.4% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $2.83, which is considered slightly high relative to its 30-day fair value range of $2.75 to $2.85. The stock's valuation (Forward PE: 19.6) is in line with its historical norms (21.1). Remarkably, the market is currently pricing in an annual earnings decline of 2.4% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is approaching resistance at $2.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $2.54. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is approaching resistance at $2.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $2.54. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.75 -
$2.85
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.1%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 10.4% above Wall St target ($2.54)
Trading Range Analysis
30-Day Trading Range
$2.75 -
$2.85
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.22
(7.7%)
Support & Resistance Levels
Support Level
$2.70
Resistance Level
$2.91
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.61
Wall Street Target
$2.54
(-10.4%)
Revenue Growth (YoY)
40.1%
Earnings Growth (YoY)
126.8%
Profit Margin
-1.1%
Valuation Discount vs History
-2.4% cheaper
PE vs Historical
19.6 vs 21.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.4%
(market-implied from PE analysis)
1-Year Target
$2.76
(-2%)
2-Year Target
$2.70
(-5%)
3-Year Target
$2.63
(-7%)
3-Yr Target (if PE normalizes)
(PE: 20→21)
$2.83
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 12.0%)
$4.21
(+49%)
Base:
(SPY PE: 19.6, Growth: 12.0%)
$3.98
(+41%)
Bear:
(PE: 16.7, Growth: 12.0%)
$3.38
(+20%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.6 to 21.1
Stabilization Target:
$3.04
(+7.6%)
PE Expansion Potential:
+7.6%
Share & Embed Analysis
Last updated: August 04, 2026 4:30 AM ET
Data refreshes hourly during market hours. Next update: 5:30 AM
Data refreshes hourly during market hours. Next update: 5:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
